ClinicalTrials.gg
CompletedNCT01512966VIVID-JapanUpdated Oct 9, 2014

Japanese Safety Study of VEGF Trap-Eye in DME (Diabetic Macular Edema)

A Phase 3 interventional study of VEGF Trap-Eye (BAY86-5321) in Macular Edema, sponsored by Bayer. Completed at 18 sites in Japan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-10-09.

Sponsored by Bayer · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
73
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 53 studies testing aflibercept in Macular Edema — 1 open to participants now, 3 under way, 1 of them phase 3. aflibercept · Macular Edema.

Enrollment
21st of 53
73 · median 49
Started
2012
with 2 others
Phase 3
11 of 53
none open now
Registered
6th of 53
by date
Lead sponsor
9 of 53
Bayer

Among the 53 studies testing aflibercept in Macular Edema, this one is the 21st largest by enrollment, is one of 3 that started in 2012, is one of 11 in phase 3, and was the 6th registered.

Macular Edema

758 studies on the registry are indexed under Macular Edema; 66 are open to participants now.

Browse Macular Edema studies →

Open to participants now

1 of the 53 studies testing aflibercept in Macular Edema is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About aflibercept

aflibercept: first FDA approval 2011 (EYLEA), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 44 Macular Edema studies recruiting now, 31 (70%) set no upper age limit and 7 (16%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 53 studies testing aflibercept in Macular Edema, or all of them as a file.
02

Study summary

This study will assess the safety and tolerability of intravitreally (IVT) administered VEGF Trap-Eye in Japanese subjects with diabetic macular edema (DME) over the period of one year.

03

Conditions studied

  • Macular Edema

Browse trials for

Keywords

  • Diabetic Macular Edema
  • DME
  • VEGF Trap-Eye
  • best-corrected visual acuity (BCVA)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults ≥ 18 years with type 1 or 2 diabetes mellitus
  • Subjects with DME (diabetic macular edema) secondary to diabetes mellitus involving the center of the macula in the study eye
  • BCVA (best-corrected visual acuity) ETDRS (Early Treatment Diabetic Retinopathy Study) letter score of 73 to 24 (20/40 to 20/320) in the study eye

Exclusion criteria

Exclusion Criteria:

  • Active proliferative diabetic retinopathy (PDR) in the study eye
  • Uncontrolled diabetes mellitus, as defined by >12%
  • Only 1 functional eye even if that eye is otherwise eligible for the study
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
73 participants (actual)

Study arms

  • Experimental
    VTE 2Q4 first, then VTE 2Q8

    VEGF Trap-Eye \[BAY86-5321; EYLEA (aflibercept) Injection\] 2 mg Q4 (VTE 2Q4) administered every 4 weeks from Week 0 to Week 16, followed by every 8 weeks until Week 48 (2Q8)

    Biological: VEGF Trap-Eye (BAY86-5321)

Interventions

  • Subjects in the VEGF Trap-Eye group will receive intravitreal injections every 8 weeks following a loading phase with injections given every 4 weeks. The overall treatment period is 48 weeks.

06

What researchers measure

Primary outcomes

  1. Adverse Event collection

    Time frame: Week 52

Secondary outcomes

  1. Change from baseline in BCVA (best corrected visual acuity) letter score

    Time frame: Week 52

07

Study locations

18 sites
  • Matsuyama, Ehime 790-8524, Japan
  • Maebashi, Gunma 371-8511, Japan
  • Kobe, Hyogo 650-0017, Japan
  • Mito, Ibaraki 310-0015, Japan
  • Kita, Kagawa 761-0793, Japan
  • Kawasaki, Kanagawa 216-8511, Japan
  • Sendai, Miyagi 984-8560, Japan
  • Kashihara, Nara 634-8522, Japan
  • Suita, Osaka 565-0871, Japan
  • Otsu, Shiga 520-2192, Japan
  • Shimotsuke, Tochigi 329-0498, Japan
  • Kagoshima, 890-8520, Japan
  • Kyoto, 606-8507, Japan
  • Okayama, 700-8558, Japan
  • Osaka, 537-0025, Japan
  • Osaka, 558-8558, Japan
  • Saga, 840-8571, Japan
  • Wakayama, 641-8510, Japan
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2012, a primary completion of Sep 2013 and a completion of Sep 2013. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 16, 2012
First posted
Jan 20, 2012
Start
Jan 2012
Primary completionActual
Sep 2013
CompletionActual
Sep 2013
Last update
Oct 9, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 9, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01512966
Lead sponsor
Bayer
Responsible party
Sponsor
First posted
Jan 20, 2012
Start date
Jan 2012
Primary completion
Sep 2013
Completion
Sep 2013
Last update
Oct 9, 2014

Study contacts

Bayer Study Director
study director · Bayer

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aflibercept

Start the discussion